Trials / Unknown
UnknownNCT02013232
Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Beijing HuiLongGuan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-01-01
- Completion
- 2014-02-01
- First posted
- 2013-12-17
- Last updated
- 2013-12-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02013232. Inclusion in this directory is not an endorsement.